Diagnose and treat constipation- or diarrhoea-predominant irritable bowel syndrome with confidence

被引：0
|
作者：
Fenton, Caroline [1 ]
Kang, Connie [1 ]
机构：
[1] Springer Nat, Private Bag 65901, Auckland 0754, New Zealand
来源：
DRUGS & THERAPY PERSPECTIVES | 2022年 / 38卷 / 04期
关键词：
MANAGEMENT; GUIDELINE;
D O I：
10.1007/s40267-022-00906-w
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Irritable bowel syndrome (IBS) is diagnosed based on clinical criteria of regular abdominal pain and disordered defaecation. If first-line treatments such as lifestyle changes fail, patients with diarrhoea-predominant IBS may respond to rifaximin, eluxadoline or, for women, alosetron, if tolerated. For constipation-predominant IBS, options are tegaserod for younger women, and the secretagogues linaclotide, plecanatide, lubiprostone and tenapanor. As IBS is a gut-brain interaction disorder, neuromodulators such as tricyclic antidepressants may help.
引用
收藏
页码：171 / 176
页数：6
相关论文
共 50 条
  • [1] Diagnose and treat constipation- or diarrhoea-predominant irritable bowel syndrome with confidence
    Caroline Fenton
    Connie Kang
    Drugs & Therapy Perspectives, 2022, 38 : 171 - 176
  • [2] Eluxadoline: A Review in Diarrhoea-Predominant Irritable Bowel Syndrome
    Gillian M. Keating
    Drugs, 2017, 77 : 1009 - 1016
  • [3] Rifaximin for the treatment of diarrhoea-predominant irritable bowel syndrome
    Laterza, Lucrezia
    Ianiro, Gianluca
    Scoleri, Iolanda
    Landi, Rosario
    Bruno, Giovanni
    Scaldaferri, Franco
    Gaetani, Eleonora
    Campanale, Mariachiara
    Gasbarrini, Antonio
    EXPERT OPINION ON PHARMACOTHERAPY, 2015, 16 (04) : 607 - 615
  • [4] Eluxadoline: A Review in Diarrhoea-Predominant Irritable Bowel Syndrome
    Keating, Gillian M.
    DRUGS, 2017, 77 (09) : 1009 - 1016
  • [5] Instability of the faecal microbiota in diarrhoea-predominant irritable bowel syndrome
    Durban, Ana
    Abellan, Juan J.
    Jimenez-Hernandez, Nuria
    Artacho, Alejandro
    Garrigues, Vicente
    Ortiz, Vicente
    Ponce, Julio
    Latorre, Amparo
    Moya, Andres
    FEMS MICROBIOLOGY ECOLOGY, 2013, 86 (03) : 581 - 589
  • [6] Cytokine profile in diarrhoea-predominant irritable bowel syndrome patients
    Sharma, S.
    Rana, S. V.
    Kaur, J.
    Bhasin, D. K.
    Ola, R. P.
    Singh, K.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2011, 26 : 105 - 105
  • [7] Is amitriptyline really effective in diarrhoea-predominant irritable bowel syndrome?
    Chassany, O.
    Duracinsky, M.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2008, 28 (03) : 371 - 372
  • [8] Rectal afferent hypersensitivity and compliance in irritable bowel syndrome: differences between diarrhoea-predominant and constipation-predominant subgroups
    Zar, Sameer
    Benson, Martin J.
    Kumar, Devinder
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2006, 18 (02) : 151 - 158
  • [9] Is amitriptyline really effective in diarrhoea-predominant irritable bowel syndrome? Reply
    Vahedi, H.
    Merat, S.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2008, 28 (03) : 372 - U3
  • [10] No benefit of faecal microbiota transplantation for diarrhoea-predominant irritable bowel syndrome
    不详
    BRITISH JOURNAL OF HOSPITAL MEDICINE, 2019, 80 (09) : 498 - 498
12345